ASC30 (Oral Small-Molecule GLP-1 Agonist)
Another entrant in the race to follow Foundayo: a once-daily oral GLP-1 pill that is a small molecule rather than a peptide, now in a global Phase 3.
Investigational compounds, read carefully
This section covers peptides at the frontier of research. Most entries are preclinical, in early or mid-stage clinical trials, or theoretical. Evidence levels are explicitly marked on every entry.
Nothing on these pages constitutes medical advice, dosing recommendations, or instructions for use. Many of these compounds are not commercially available; some are not legal for human use. Decisions about treatment require a qualified clinician.
At a glance
ASC30 is a once-daily oral GLP-1 receptor agonist from Ascletis Pharma. It is a small molecule, not a peptide. Its global Phase 3 programme, AURORA-1 and AURORA-2, will enrol about 4,600 adults for 72 weeks and dosed its first participant on August 30, 2026. Topline results are expected in the third quarter of 2028. A 13-week Phase 2 reported up to 7.7% placebo-adjusted weight loss at the highest dose.
- Class
- Small molecule, oral GLP-1 receptor agonist — not a peptide
- Sponsor
- Ascletis Pharma
- Stage
- Phase 3 (AURORA-1, AURORA-2)
- Target
- Chronic weight management
What it is
ASC30 is an oral GLP-1 receptor agonist taken once a day. Like orforglipron, approved in the US as Foundayo in April 2026, it is a small molecule. That means it can be absorbed from the gut without the special formulation that oral semaglutide requires, and it is cheaper and simpler to manufacture than a peptide.
It is not a peptide, and we cover it because it competes directly with the peptide GLP-1 drugs for the same patients. The oral small-molecule field also includes aleniglipron and elecoglipron, and it has seen setbacks, including Pfizer's danuglipron, discontinued in 2025.
Current research status
The global Phase 3 programme consists of AURORA-1 (NCT07743463) and AURORA-2 (NCT07743450), together about 4,600 adults, testing 20, 40, and 60 mg doses over 72 weeks. The first participant was dosed on August 30, 2026. Ascletis expects topline results in the third quarter of 2028 and plans an FDA filing by the end of 2028. ASC30 is investigational and not approved anywhere.
Mechanistic rationale
ASC30 activates the GLP-1 receptor, reducing appetite and slowing stomach emptying in the same way as the injectable drugs. The difference is in delivery. Peptides are broken down in the digestive tract, which is why oral semaglutide needs an absorption enhancer and strict dosing conditions. A small molecule avoids that problem, which is what makes once-daily pills without food restrictions possible. Our guide to oral versus injectable GLP-1s covers the trade-offs.
Available evidence
Why it's interesting
Oral small-molecule GLP-1 drugs could expand access substantially, because they are easier to manufacture at scale and avoid injections. A large, global Phase 3 shows Ascletis is pursuing the full regulatory path rather than a regional one.
Limitations & risks
The efficacy evidence so far is a short Phase 2. The class has a mixed safety record, with several candidates dropped during development, and liver safety is a recurring point of scrutiny. Results are not expected until 2028, by which time Foundayo will have years of market experience and other oral candidates will have reported.
Community discussion notes
ASC30 has had little community discussion. It is investigational and not available outside clinical trials, and anything marketed under that name is not the investigational drug.
The oral race, in context
ASC30 is a credible entrant in a crowded field, with a large Phase 3 and a long wait for results. Its commercial prospects will depend less on whether it works than on whether it offers an advantage over Foundayo, the oral small-molecule GLP-1 already on the market.
Frequently asked questions
Is ASC30 a peptide?
No. ASC30 is a small molecule. It acts on the same GLP-1 receptor as peptide drugs such as semaglutide but is chemically different, which is why it can be taken as a simple daily pill.
How does it compare with Foundayo?
Both are once-daily oral small-molecule GLP-1 agonists. Foundayo (orforglipron) has been approved in the US since April 2026, while ASC30 began Phase 3 in August 2026. No comparison of efficacy is possible yet.
When will results come?
Ascletis expects topline Phase 3 results in the third quarter of 2028 and plans an FDA filing by the end of 2028.
Is ASC30 available?
No. It is investigational and available only in clinical trials.
References
- Ascletis Pharma. First participant dosed in a global Phase III clinical programme of ASC30. August 2026. https://www.placera.se/pressmeddelanden/ascletis-announces-first-participant-dosed-in-a-global-phase-iii-clinical-program-of-once-daily-oral-small-molecule-glp-1-receptor-agonist-asc30-for-chronic-weight-management-20260830
- The Pharma Letter. Ascletis posts encouraging Phase II data for oral obesity drug. December 2025. https://www.thepharmaletter.com/pharma-news/ascletis-posts-encouraging-phase-ii-data-for-oral-obesity-drug